These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10706989)

  • 1. 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review.
    Olivier B; van Wijngaarden I; Soudijn W
    Eur Neuropsychopharmacol; 2000 Mar; 10(2):77-95. PubMed ID: 10706989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limbic mechanisms of anxiolytics acting on 5-HT receptors.
    Płaźnik A; Kostowski W; Stefański R
    Pol J Pharmacol; 1994; 46(5):473-7. PubMed ID: 7894537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety.
    Griebel G; Rodgers RJ; Perrault G; Sanger DJ
    Neuropharmacology; 2000 Jul; 39(10):1848-57. PubMed ID: 10884565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data.
    Wesołowska A
    Pharmacol Rep; 2010; 62(4):564-77. PubMed ID: 20884998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiolytic potential of 5-HT3 receptor antagonists.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Mar; 70(3):157-62. PubMed ID: 1349746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
    Dekeyne A; Brocco M; Adhumeau A; Gobert A; Millan MJ
    Psychopharmacology (Berl); 2000 Sep; 152(1):55-66. PubMed ID: 11041316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.
    Barrett JE; Vanover KE
    Psychopharmacology (Berl); 1993; 112(1):1-12. PubMed ID: 7870996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism.
    Eguchi J; Inomata Y; Saito K
    Pharmacol Biochem Behav; 2001 Apr; 68(4):677-83. PubMed ID: 11526964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety.
    Nic Dhonnchadha BA; Bourin M; Hascoët M
    Behav Brain Res; 2003 Mar; 140(1-2):203-14. PubMed ID: 12644293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiolytic-like effects of DAIZAC, a selective high-affinity 5-HT(3) receptor antagonist, in the mouse elevated plus-maze.
    Zhang ZJ; Schmidt DE; de Paulis T; Trivedi BL; Onaivi ES; Ebert MH; Hewlett WA
    Pharmacol Biochem Behav; 2001; 69(3-4):571-8. PubMed ID: 11509218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic mechanisms in anxiety.
    Eison AS; Eison MS
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan; 18(1):47-62. PubMed ID: 8115673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of forced swimming-induced stress on the anxiolytic-like effect of 5HT(1A) agents in mice.
    Briones-Aranda A; López-Rubalcava C; Picazo O
    Psychopharmacology (Berl); 2002 Jul; 162(2):147-55. PubMed ID: 12110992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations.
    Kehne JH; McCloskey TC; Baron BM; Chi EM; Harrison BL; Whitten JP; Palfreyman MG
    Eur J Pharmacol; 1991 Feb; 193(3):283-92. PubMed ID: 1675993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical utility of pharmacological agents that act at serotonin receptors.
    Peroutka SJ; Sleight AJ; McCarthy BG; Pierce PA; Schmidt AW; Hekmatpanah CR
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):253-62. PubMed ID: 2562495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiolytic-like effect of way-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience.
    Canto-de-Souza A; Luiz Nunes-de-Souza R; Rodgers RJ
    Brain Res; 2002 Feb; 928(1-2):50-9. PubMed ID: 11844471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5-HT1A receptor and its ligands: structure and function.
    Olivier B; Soudijn W; van Wijngaarden I
    Prog Drug Res; 1999; 52():103-65. PubMed ID: 10396127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
    Bill DJ; Coleman J; Hallett I; Middlefell VC; Rhodes KF; Fletcher A
    Br J Pharmacol; 1995 Jul; 115(5):775-80. PubMed ID: 8548176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice.
    Cao BJ; Rodgers RJ
    Psychopharmacology (Berl); 1998 Oct; 139(3):185-94. PubMed ID: 9784072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.
    Silverstone PH; Cowen PJ
    Biol Psychiatry; 1994 Sep; 36(5):309-16. PubMed ID: 7993957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-life blockade of 5-HT(1A) receptors alters adult anxiety behavior and benzodiazepine sensitivity.
    Vinkers CH; Oosting RS; van Bogaert MJ; Olivier B; Groenink L
    Biol Psychiatry; 2010 Feb; 67(4):309-16. PubMed ID: 19811773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.